Euroopan unioni - italia - EMA (European Medicines Agency)

teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - farmaci per le malattie respiratorie ostruttive, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).

Euroopan unioni - italia - EMA (European Medicines Agency)

covis pharma europe b.v. - aclidinium bromuro, formoterolo fumarato diidrato - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - duaklir genuair è indicato come trattamento broncodilatatore di mantenimento per alleviare i sintomi in pazienti adulti con malattia polmonare ostruttiva cronica (bpco).

Euroopan unioni - italia - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a. - beclometasone dipropionato, formoterolo fumarato diidrato, glycopyrronium bromuro - malattia polmonare, ostruttiva cronica - farmaci per le malattie respiratorie ostruttive, - maintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and high dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year. copdmaintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (copd) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting beta2-agonist or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (for effects on symptoms control and prevention of exacerbations see section 5. asthmamaintenance treatment of asthma, in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist and medium dose of inhaled corticosteroid, and who experienced one or more asthma exacerbations in the previous year.

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

chiesi sa - beclometasoni dipropionas, formoteroli fumaras dihydricus, glycopyrronium - solution pour inhalation en flacon pressurisé - beclometasoni dipropionas 87.4 µg, formoteroli fumaras dihydricus 5.2 µg, glycopyrronii bromidum 10.9 µg corresp. glycopyrronium 9 µg, ethanolum anhydricum 8.856 mg, acidum hydrochloridum, norfluranum, ad aerosolum, pro dosi. - bronchopneumopathie chronique obstructive (bpco) (trimbow 87/5/9 mcg), asthme (trimbow 172/5/9 mcg) - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum, glycopyrronium, formoteroli fumaras dihydricus - druckgasinhalation, suspension - budesonidum 160 µg, glycopyrronii bromidum 9 µg corresp. glycopyrronium 7.2 µg, formoteroli fumaras dihydricus 5 µg, 1,2-distearoyl-sn-glycero-3-phosphocholinum, calcii chloridum dihydricum, norfluranum, ad suspensionem pro dosi. - bpco - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

chiesi sa - beclometasoni dipropionas, formoteroli fumaras dihydricus, glycopyrronium - solution pour inhalation en flacon pressurisé - beclometasoni dipropionas 172.3 µg, formoteroli fumaras dihydricus 5 µg, glycopyrronii bromidum 10.6 µg corresp. glycopyrronium 9 µg, ethanolum anhydricum 8.856 mg, acidum hydrochloridum, norfluranum, ad aerosolum, pro dosi. - bronchopneumopathie chronique obstructive (bpco) (trimbow 87/5/9 mcg), asthme (trimbow 172/5/9 mcg) - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum, formoteroli fumaras dihydricus - polvere per inalazione - budesonidum 100 µg, formoteroli fumaras dihydricus 6 µg, lactosum monohydricum, ad pulverem pro dosi. - antiasthmatikum, la bpco - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum, formoteroli fumaras dihydricus - polvere per inalazione - budesonidum 200 µg, formoteroli fumaras dihydricus 6 µg, lactosum monohydricum, ad pulverem pro dosi. - antiasthmatikum, la bpco - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum, formoteroli fumaras dihydricus - polvere per inalazione - budesonidum 400 µg, formoteroli fumaras dihydricus 12 µg, lactosum monohydricum, ad pulverem pro dosi, doses pro vase 60. - antiasthmatikum, la bpco - synthetika

Sveitsi - italia - Swissmedic (Swiss Agency for Therapeutic Products)

astrazeneca ag - budesonidum, formoteroli fumaras dihydricus - dosieraerosol - budesonidum 100 µg, formoteroli fumaras dihydricus 6 µg, povidonum k 25, macrogolum 1000, apafluranum, ad aerosolum pro dosi corresp. 74.6 mg. doses pro vase 120. - asma bronchiale, bpco - synthetika